

# Neonatal Parenteral Information

November 29, 2022 09:03 AM

## acetaminophen

### Administration Information

#### IV Intermittent Infusion

##### Standard Concentration

10 mg/mL [Supplied in Standard Concentration]

##### Administration Duration

00:15 (hh:mm)

##### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

## acetylcysteine

**The contents of this page correspond to order set IWK INNAC "Intravenous N-Acetylcysteine Protocol for Acute Acetaminophen Overdose". If not being used in this context, please contact pharmacy or Poison Centre**

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration and use SINGLE CONCENTRATION protocol](#)

### Administration Information

#### IV Continuous

##### Standard Concentration

30 mg/mL

##### Monitoring

As per clinical order set IWK INNAC

##### Comment

**Prepare bag to a final concentration of 30 mg/mL.**

<b>100 mL</b>	<ol style="list-style-type: none"> <li>1. Remove 15 mL from 100 mL bag of dextrose 5% or sodium chloride 0.9%</li> <li>2. Add 15 mL of NAC 200 mg/mL (20%) to 85 mL for a final volume of 100 mL</li> </ol>
---------------	---

#### Tips for BBraun Pump Programming:

- Use large volume pump and PICU Library entry
- Program the VTBI as directed below
- **DO NOT adjust the time** - The time does not take the loading dose into consideration and if adjusted to 21 hours before the loading dose has been administered, your pump will alarm at the incorrect time

**VTBI for 21 hour infusion (Loading Dose plus 20 hour infusion) = 15 mL/kg x patient weight (kg)**

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

#### Additional Information

##### Potential Hazards of Administration

- Hypersensitivity reactions have been reported: rash, urticaria, facial edema, hypotension/hypertension, tachycardia, bronchospasm, anaphylaxis

## acyclovir

### EXTRAVASATION RISK / IRRITANT

#### Administration Information

#### IV Intermittent Infusion

##### Standard Concentration

7 mg/mL

##### Administration Duration

01:00 (hh:mm)

##### Monitoring

Level 2: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours) AND Urine Output

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Compatibility Information

##### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

#### Additional Information

##### Comments

- Ensure adequate hydration during and for at least 2 hours following administration to prevent drug precipitation in kidneys
  - Manufacturer suggests 1 litre of fluid/24 hours/gram of acyclovir and recommends a minimum urine output of 500 mL/24 hours/gram of acyclovir

---

## adenosine

### HIGH ALERT

#### Administration Information

#### IV Direct- Doses less than 0.3 mg

##### Standard Concentration

0.5 mg/mL

##### Administration Duration

2 seconds

##### Monitoring

Level 3: Level 2 and continuous ECG

##### Comment

May be given directly into a vein or via peripheral IV site closest to patient's heart. Follow with rapid flush. Administration into lower extremity may cause treatment failure.

#### IV Direct- Doses greater than or equal to 0.3 mg

##### Standard Concentration

3 mg/mL [Supplied in Standard Concentration]

##### Administration Duration

2 seconds

##### Monitoring

Level 3: Level 2 and continuous ECG

##### Comment

May be given directly into a vein or via peripheral IV site closest to patient's heart. Follow with rapid flush. Administration into lower extremity may cause treatment failure.

#### Compatibility Information

##### Compatible Solutions

0.9% Sodium Chloride (NaCl)

#### Additional Information

**Potential Hazards of Administration**

- Dyspnea, chest pressure
  - Facial flushing
- 

*alprostadil***HIGH ALERT, EXTRAVASATION RISK / IRRITANT***Administration Information**IV Continuous Infusion***Standard Concentration**

6 micrograms/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED***Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

*Additional Information***Potential Hazards of Administration**

- Apnea (especially in patient less than 2 kg and generally occurs within first hour of administration. Occurs in 10-12% of neonates)
  - Hypotension, bradycardia
  - Fever
  - Cutaneous flushing (with rapid infusion rate)
  - Edema
- 

*alteplase (CVAD occlusion/parapneumonic effusion)***HIGH ALERT***Administration Information**Instillation***Standard Concentration**

1 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

Refer to manufacturer insert provided for information on drug reconstitution and preparation.

---

*aminophylline**Administration Information**IV Continuous Infusion- Patients less than or equal to 2 kg***Standard Concentration**

2 mg/mL

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Continuous Infusion- Patients greater than 2 kg***Standard Concentration**

5 mg/mL

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

### Additional Information

#### Potential Hazards of Administration

- Tachycardia
- Nausea/Vomiting
- Jitteriness/nervousness, headache, insomnia
- Muscle cramps, hyperreflexia
- Seizures

#### Comments

aminophylline 100 mg = theophylline 80 mg

## amiodarone

### HIGH ALERT, EXTRAVASATION RISK / IRRITANT

**FILTER** 0.22 micron in-line filter

### Administration Information

*IV Intermittent Infusion / Loading Dose (followed by continuous infusion)*

#### Standard Concentration

6 mg/mL

#### Administration Duration

01:00 (hh:mm)

#### Monitoring

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Central Line PREFERRED

#### Comment

- Administration duration may be increased to reduce hypotension

*IV Continuous Infusion- Patients less than or equal to 1 kg*

#### Standard Concentration

2 mg/mL

#### Monitoring

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*IV Continuous Infusion- Patients greater than 1 kg via PERIPHERAL line*

#### Standard Concentration

2 mg/mL

#### Monitoring

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*IV Continuous Infusion- Patients greater than 1 kg via CENTRAL line*

#### Standard Concentration

6 mg/mL

#### Monitoring

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

### Compatibility Information

#### Compatible Solutions

5% Dextrose in Water (D5W)

### Additional Information

#### Potential Hazards of Administration

- Hypotension (may be related to infusion rate)

#### Comments

- Do not mix or flush with 0.9% sodium chloride
- Do not use empty evacuated bottles for administration as precipitation may result
- May be mixed in a syringe (syringes do not contain PVC). PVC tubing may be used for administration
- Diluted solutions are stable for 2 hours in polyvinyl chloride (PVC) bags. If duration of infusion is more than 2 hours, use in a non-PVC container.

---

## *amphotericin B deoxycholate (conventional)*

**HIGH ALERT, EXTRAVASATION RISK / IRRITANT**

### Administration Information

#### IV Intermittent Infusion

#### Standard Concentration

0.1 mg/mL

#### Administration Duration

02:00 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Comment

- Flush line with D5W before and after administration

### Compatibility Information

#### Compatible Solutions

10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

### Additional Information

#### Potential Hazards of Administration

- Infusion reaction: Acute reactions (eg, fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur within 1 to 3 hours of beginning infusion. Typically more common with the first few doses and generally lessens with subsequent doses.

---

## *amphotericin B liposomal*

**HIGH ALERT**

**FILTER** Withdraw the amount of reconstituted solution (4 mg/mL) into a syringe. Attach the 5 micron filter provided to the syringe.

Inject the contents of the syringe into the appropriate volume of D5W to obtain standard concentration (2 mg/mL)

### Administration Information

#### IV Intermittent Infusion

#### Standard Concentration

2 mg/mL

#### Administration Duration

02:00 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### Comment

- Do not mix with any saline containing solutions
- Flush with D5W

#### Compatibility Information

##### Compatible Solutions

5% Dextrose in Water (D5W)

#### Additional Information

##### Potential Hazards of Administration

- Infusion reaction: Acute reactions (eg, fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur within 1 to 3 hours of beginning infusion. Typically more common with the first few doses and generally lessens with subsequent doses.

## ampicillin

Pharmacy does not prepare due to limited stability

#### Administration Information

##### IV Direct- General Dosing

##### Standard Concentration

100 mg/mL [Supplied in Standard Concentration]

##### Administration Duration

00:05 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

##### IV Intermittent Infusion- Meningitis

##### Standard Concentration

100 mg/mL [Supplied in Standard Concentration]

##### Administration Duration

00:15 (hh:mm)

##### Maximum Rate of Administration

10 mg/kg/min

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

##### Intramuscular

##### Standard Concentration

IM 250 mg/mL [Supplied in Standard Concentration]

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

## arginine

### EXTRAVASATION RISK / IRRITANT

**When used as management of hyperammonemia, there is additional administration related information provided on the clinical order set (IWK EMMA)- see Drug Dosing Guideline**

#### Administration Information

##### IV Intermittent Infusion- Hyperammonemia /Urea Cycle Disorder (UCD) Loading Dose

##### Standard Concentration

100 mg/mL

**Administration Duration**

01:30 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED**

*IV Continuous Infusion- Hyperammonemia/Urea Cycle Disorder (UCD) Maintenance*

**Standard Concentration**

100 mg/mL

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED**

*Compatibility Information*

**Compatible Solutions**

10% Dextrose in Water (D10W)

*Additional Information*

**Potential Hazards of Administration**

- Infusion-related reactions: rapid infusion may result in flushing, nausea, or vomiting
- Hypotension and vasodilation

*atropine*

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

*Administration Information*

*IV Direct*

**Standard Concentration**

0.1 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:01 (hh:mm)

**Monitoring**

Level 3: Level 2 and continuous ECG

*Intramuscular*

**Standard Concentration**

0.1 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

*Additional Information*

**Potential Hazards of Administration**

- Paradoxical:
  - bradycardia- particularly if injections given slower than recommendation (1 minute)
  - hyperexcitability-particularly with large doses
- Rapid rise in body temperature -children are at increased risk due to suppression of sweat gland activity

## azithromycin

### EXTRAVASATION RISK / IRRITANT

#### Administration Information

##### IV Intermittent Infusion

###### Standard Concentration

2 mg/mL

###### Administration Duration

01:00 (hh:mm)

###### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Compatibility Information

##### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

#### Additional Information

##### Potential Hazards of Administration

- Injection site pain and inflammation
- 

## caffeine

#### Administration Information

##### IV Intermittent Infusion- Loading Dose

###### Standard Concentration

10 mg(base)/mL [Supplied in Standard Concentration]

###### Administration Duration

00:30 (hh:mm)

###### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

##### IV Intermittent Infusion- Maintenance Dose

###### Standard Concentration

10 mg(base)/mL [Supplied in Standard Concentration]

###### Administration Duration

00:10 (hh:mm)

###### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

## calcium gluconate

### HIGH ALERT, EXTRAVASATION RISK / IRRITANT

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

#### Administration Information

##### IV Intermittent Infusion

###### Standard Concentration

50 mg/mL

###### Administration Duration

00:30 (hh:mm)

###### Monitoring

Level 3: Level 2 and continuous ECG



The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Comment**

- Administer via a large vein. Do not administer through scalp vein, small hand or foot vein.

*IV Continuous Infusion*

**Standard Concentration**

50 mg/mL

**Maximum Rate of Administration**

35 mg/kg/hour

**Monitoring**

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Comment**

- Administer via a large vein. Do not administer through scalp vein, small hand or foot vein.

*Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

*Additional Information*

**Potential Hazards of Administration**

- Vasodilation, hypotension, bradycardia, cardiac arrhythmias (with rapid IV administration)
  - Discontinue infusion if heart rate less than 100 beats/minute in neonates.

*caspofungin*

**EXTRAVASATION RISK / IRRITANT**

*Administration Information*

*IV Intermittent Infusion*

**Standard Concentration**

0.45 mg/mL

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Comment**

- Do not mix with dextrose containing solutions

*Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), Lactated Ringer's (LR)

*Additional Information*

**Potential Hazards of Administration**

- Histamine-related effects: rash, facial swelling, sensation of warmth, angioedema, pruritis, bronchospasm
- Fever, Chills
- Hypotension

*ceFAZolin*

### *Administration Information*

#### *IV Direct*

**Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### *Intramuscular*

**Standard Concentration**

IM 250 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

Inject into large muscle

---

### *cefoTAXime*

#### *Administration Information*

#### *IV Direct*

**Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

Administration over less than 1 minute may cause life -threatening arrhythmias

#### *Intramuscular*

**Standard Concentration**

IM 250 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

Inject into large muscle

---

### *ceFOXitin*

#### *Administration Information*

#### *IV Intermittent Infusion*

**Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:15 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

### *ceftAZIDime*

- Carbon dioxide is released during reconstitution causing pressure within vial. Vent with needle prior to withdrawing. Expel bubbles prior to injection

### Administration Information

#### IV Direct

**Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### Intramuscular

**Standard Concentration**

IM 250 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

- Inject into large muscle

### cefTRIAxone

- **DO NOT mix cefTRIAxone with, or administer simultaneously or via Y-site with ANY calcium-containing IV solutions, including TPN and Lactated Ringers, as precipitation can occur.**
- **\* Lidocaine is the PREFERRED DILUENT FOR RECONSTITUTION to minimize discomfort of IM injection WHEN A PATIENT is GREATER THAN 5 KG. Patients 5 kg or less should use sterile water as diluent. Include documentation of use of lidocaine as diluent on medication admin record.**

### Administration Information

#### Intramuscular

**Standard Concentration**

350 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

**\* Lidocaine is the PREFERRED DILUENT FOR RECONSTITUTION to minimize discomfort of IM injection WHEN A PATIENT is GREATER THAN 5 KG. Patients 5 kg or less should use sterile water as diluent. Include documentation of use of lidocaine as diluent on medication admin record.**

### Compatibility Information

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

### Additional Information

**Potential Hazards of Administration**

- Diarrhea
- Rash
- Hypersensitivity reaction
- Hemolytic anemia
- Altered prothrombin time
- Eosinophilia, thrombocytopenia
- Pancreatitis, reversible cholelithiasis
- Elevated liver enzymes, elevated BUN and creatinine
- Injection site reactions

**Comments**

- Increased risk of nephrotoxicity in patients receiving concurrent nephrotoxic medications such as aminoglycosides.

## *ciprofloxacin*

### **EXTRAVASATION RISK / IRRITANT**

**Reserved/Restricted : Infectious Disease, Urology or Patients with Cystic Fibrosis**

#### *Administration Information*

##### *IV Intermittent Infusion*

###### **Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

###### **Administration Duration**

01:00 (hh:mm)

###### **Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

###### **Comment**

- Use a large vein to reduce risk of venous irritation.
- 

## *cisatracurium*

### **HIGH ALERT**

#### *Administration Information*

##### *IV Direct*

###### **Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

###### **Administration Duration**

10 seconds

###### **Monitoring**

Level 3: Level 2 and continuous ECG

##### *IV Continuous Infusion*

###### **Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

###### **Maximum Rate of Administration**

10 microgram/kg/min

###### **Monitoring**

Level 3: Level 2 and continuous ECG

###### **Comment**

When continuous infusion is running, bolus doses can be administered over 10 seconds (using the bolus function)

#### *Additional Information*

###### **Potential Hazards of Administration**

- Wheezing, bronchospasm, laryngospasm (rare)
- 

## *clindamycin*

### **EXTRAVASATION RISK / IRRITANT**

#### *Administration Information*

##### *IV Intermittent Infusion*

###### **Standard Concentration**

12 mg/mL [Supplied in Standard Concentration]

###### **Administration Duration**

00:30 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*Intramuscular***Standard Concentration**

IM 150 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Comment**

Ability to use intramuscular route may be limited by dose/volume.

---

*cloxacillin***EXTRAVASATION RISK / IRRITANT***Administration Information**IV Direct***Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

---

*cosyntropin**Administration Information**IV Direct- Doses less than 125 micrograms***Standard Concentration**

10 micrograms/mL

**Administration Duration**

00:02 (hh:mm)

*Intramuscular***Standard Concentration**

250 micrograms/mL [Supplied in Standard Concentration]

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl)

---

*dexamethasone**Administration Information**IV Direct- Doses less than 0.05 mg***Standard Concentration**

0.025 mg/mL

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Direct- Doses 0.05 to 1 mg*

**Standard Concentration**

0.5 mg/mL

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Direct- Doses greater than 1 mg*

**Standard Concentration**

10 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Compatibility Information****Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

**dexmedetomidine****HIGH ALERT**

**Reserved/Restricted : Continuous Infusion is restricted to Pediatric Acute Pain Service and Advanced Care when ordered outside of PICU, OR/PACU, NICU, ED**

**Administration Information**

*IV Intermittent Infusion- Loading Dose*

**Standard Concentration**

4 micrograms/mL [Supplied in Standard Concentration]

**Administration Duration**

00:10 (hh:mm)

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

*IV Continuous Infusion*

**Standard Concentration**

4 micrograms/mL [Supplied in Standard Concentration]

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

**dextrose****HIGH ALERT**

[Go to PALS Calculator for administration information](#)

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

**Dextrose concentration, administration time, infusion rate and route are dependent upon clinical indication and patient's clinical status.**

[Available dextrose containing IV solutions at IWK Supply and Distribution](#)

Click [here](#) for information on dextrose containing solutions prepared by pharmacy.

Click [here](#) for information on how to prepare dextrose bags after hours when required concentration is not available.

### Administration Information

#### IV Infusion

##### Comment

Generally the following maximum concentrations apply:

- **Peripheral:** D12.5W
- **Central:** D25W

#### IV Intermittent Infusion

##### Standard Concentration

0.1 g/mL [Supplied in Standard Concentration]

##### Administration Duration

00:10 (hh:mm)

##### Monitoring

As per clinical order set IWK ORGL

### Compatibility Information

#### Compatible Solutions

Sterile Water for Injection (SWI)

### Additional Information

#### Potential Hazards of Administration

- Pain, phlebitis and thrombosis at injection site (due to rapid administration if peripheral vein used)

#### Comments

- D5W (dextrose 5% in water) = 0.05 g/mL or 50 mg/mL
- D10W (dextrose 10% in water) = 0.1 g/mL or 100 mg/mL
- D12.5W (dextrose 12.5% in water) = 0.125 g/mL or 125 mg/mL
- D25W (dextrose 25% in water) = 0.25 g/mL or 250 mg/mL
- D50W (dextrose 50% in water) = 0.5 g/mL or 500 mg/mL

## digoxin

### HIGH ALERT, EXTRAVASATION RISK / IRRITANT

### Administration Information

#### IV Intermittent Infusion

##### Standard Concentration

10 micrograms/mL

##### Administration Duration

00:10 (hh:mm)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

## DOBUTamine

### HIGH ALERT, EXTRAVASATION RISK / IRRITANT

### Administration Information

#### IV Continuous Infusion- Patients less than or equal to 2 kg

**Standard Concentration**

2 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED****Comment**

- Administration through umbilical artery catheter or peripheral vessels is not recommended however in certain situations it may be given into a large peripheral vein when necessary.

*IV Continuous Infusion- Patients greater than 2 kg***Standard Concentration**

5 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED****Comment**

- Administration through umbilical artery catheter or peripheral vessels is not recommended however in certain situations it may be given into a large peripheral vein when necessary.

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W), 5% Dextrose in Water (D5W) AND 0.9% Sodium Chloride (NaCl), Lactated Ringer's (LR)

*Additional Information***Potential Hazards of Administration**

- Tachycardia

*DOPamine***HIGH ALERT, EXTRAVASATION RISK / IRRITANT***Administration Information**IV Continuous Infusion- Patients less than or equal to 2 kg***Standard Concentration**

1600 micrograms/mL [Supplied in Standard Concentration]

**Monitoring**

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED****Comment**

- Administration through umbilical artery catheter or peripheral vessels is NOT recommended

*IV Continuous Infusion- Patients greater than 2 kg***Standard Concentration**

3200 micrograms/mL [Supplied in Standard Concentration]

**Monitoring**

Level 3: Level 2 and continuous ECG



The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Central Line PREFERRED

#### Comment

- Administration through umbilical artery catheter or peripheral vessels is NOT recommended

#### Additional Information

#### Potential Hazards of Administration

- Tachycardia, arrhythmias, ectopic heartbeats
- Hypertension or hypotension
- Blanching at site, Vasoconstriction

#### Comments

- Do not use solution if darker than slightly yellow
- Injection may contain sulfites. May cause a hypersensitivity reaction in susceptible patients

### *enalaprilat*

#### Non-Formulary

#### Administration Information

#### *IV Intermittent Infusion- Doses less than 0.25 mg*

#### Standard Concentration

0.025 mg/mL

#### Administration Duration

00:05 (hh:mm)

#### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

### *enoxaparin*

#### HIGH ALERT

**Reserved/Restricted : Hematology-Oncology, PICU Intensivists**

#### Administration Information

#### *Subcutaneous*

#### Standard Concentration

Subcutaneous 100 mg/mL [Supplied in Standard Concentration]

#### Monitoring

As per clinical order set IWK PREN or IWK THEN

#### Comment

- For doses less than 5 mg (0.05 mL): use 50 unit (0.5 mL) **insulin syringes**  
NOTE: 1 unit on insulin syringe = 1 mg enoxaparin = 0.01 mL
- For doses 5 mg (0.05 mL) and greater: use **tuberculin syringe**
- The recommended site for injection is the fat of the lower abdomen. Injection should be at least 5 centimeters away from the belly button and out towards the side. Select a different site of lower abdomen for each injection, alternating the left and right sides. Do not rub injection site after administration as bruising may occur.
- When using commercial pre-filled syringes, do not expel air bubble prior to administration.
- Enoxaparin 300 mg/3 mL multidose vial contains benzyl alcohol and should be avoided in neonates

- During regular pharmacy hours, pharmacy will prepare doses for neonatal patients using the preservative free syringes. If dose(s) are needed for neonates after regular pharmacy hours, it is acceptable to use the multidose vial for one or two doses until pharmacy is able to supply.

---

## EPINEPHrine

### HIGH ALERT, EXTRAVASATION RISK / IRRITANT

[Go to Neonatal Resuscitation Calculator for administration information in this context](#)

#### Administration Information

*IV Continuous Infusion- Patients less than or equal to 20 kg*

##### Standard Concentration

0.05 mg/mL

##### Monitoring

Level 4: Level 3 and invasive hemodynamic monitoring and/or respiratory support (continuous)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

##### Central Line PREFERRED

#### Compatibility Information

##### Compatible Solutions

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

---

## epoprostenol

### HIGH ALERT

**Reserved/Restricted : Intensivists, Neonatologists and/or consultation with Respiriology**

**FILTER** 0.22 micron in-line filter

- **NOTE: 1 NANOgram = 0.001 microgram**

#### Administration Information

*IV Continuous Infusion- Patients less than or equal to 2 kg*

##### Standard Concentration

0.5 micrograms/mL

##### Monitoring

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

##### Central Line PREFERRED

##### Comment

- Peripheral line may be used in emergency situations (ideally 12 hours or less).

*IV Continuous Infusion- Patients greater than 2 kg*

##### Standard Concentration

3 micrograms/mL

##### Monitoring

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

##### Central Line PREFERRED

##### Comment

- Peripheral line may be used in emergency situations (ideally 12 hours or less).

#### Compatibility Information

##### Compatible Solutions

0.9% Sodium Chloride (NaCl)

---

## *esmolol*

**HIGH ALERT, EXTRAVASATION RISK / IRRITANT**

### *Administration Information*

#### *IV Continuous Infusion*

##### **Standard Concentration**

10 mg/mL [Supplied in Standard Concentration]

##### **Monitoring**

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Central Line PREFERRED**

---

## *famotidine*

**November 2020 - replaces IV ranitidine as formulary injectable H2 blocker**

### *Administration Information*

#### *IV Direct*

##### **Standard Concentration**

4 mg/mL

##### **Administration Duration**

00:02 (hh:mm)

##### **Maximum Rate of Administration**

10 mg/min

##### **Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

### *Compatibility Information*

##### **Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W), Lactated Ringer's (LR), Sterile Water for Injection (SWI)

---

## *fat emulsion (Intralipid)*

**HIGH ALERT**

- [Go to IWK Intralipid Compatibility Chart for information on compatibility](#)
- [Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

### *Administration Information*

#### *IV Continuous*

##### **Standard Concentration**

0.2 g/mL [Supplied in Standard Concentration]

---

## *fat emulsion (SMOF)*

**HIGH ALERT**

- [Go to IWK SMOF Compatibility Chart for information on compatibility](#)

### *Administration Information*

#### *IV Continuous*

##### **Standard Concentration**

0.2 g/mL [Supplied in Standard Concentration]

---

## fentaNYL

### HIGH ALERT

**Reserved/Restricted : Outside of NICU/PICU/OR/PACU/ED, the use of continuous infusion is restricted to Pediatric Acute Pain Service (APS) and Pediatric Advanced Care Team (PACT). Transdermal patch- prescribing and management is restricted to prescribers with Pediatric Acute Pain Service (APS) or Pediatric Advanced Care Team (PACT).**

### Administration Information

*IV Direct- for pre-intubation or for intubated patients only*

#### Standard Concentration

2 micrograms/mL [Supplied in Standard Concentration]

#### Administration Duration

5 seconds

### IV Intermittent Infusion

#### Standard Concentration

2 micrograms/mL [Supplied in Standard Concentration]

#### Administration Duration

00:05 (hh:mm)

### IV Continuous Infusion

#### Standard Concentration

10 micrograms/mL [Standard Concentration Prepared by Pharmacy]

#### Monitoring

As per clinical order set IWK FECOIN

#### Comment

When continuous infusion is running, bolus (intermittent) doses can be administered over 5 minutes using "BOLUS" function. Bolus may be administered over seconds in critical care areas.

### Additional Information

#### Potential Hazards of Administration

- Skeletal muscle and chest wall rigidity, impaired ventilation, respiratory depression, apnea or bronchospasm have occurred with rapid administration of doses.

## filgrastim

### Administration Information

*Subcutaneous- Doses less than 300 micrograms*

#### Standard Concentration

Subcutaneous 300 micrograms/mL [Supplied in Standard Concentration]

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### Comment

- Preferred route of admin.
- Use vial. Vial contains polysorbate 80. In premature neonates, may cause thrombocytopenia, ascites, pulmonary deterioration, renal and hepatic failure.

### IV Intermittent Infusion

#### Standard Concentration

20 micrograms/mL

#### Administration Duration

00:15 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### Comment

- Remove vial from fridge approximately 30 minutes prior to injection to allow it to reach room temperature.
- Do NOT dilute use 0.9% NaCl as diluent (precipitate may form)

### *Compatibility Information*

#### **Compatible Solutions**

5% Dextrose in Water (D5W)

---

### *fish oil emulsion*

#### **HIGH ALERT**

#### *Administration Information*

##### *IV Continuous*

#### **Standard Concentration**

0.1 g/mL [Supplied in Standard Concentration]

#### **Maximum Rate of Administration**

0.05 grams/kg/hour

#### **Comment**

- Infuse in original container, use vented infusion sets.
- 

### *fluconazole*

#### *Administration Information*

##### *IV Intermittent Infusion*

#### **Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

#### **Administration Duration**

01:00 (hh:mm)

#### **Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

### *furosemide*

#### *Administration Information*

##### *IV Direct- Doses less than 1 mg*

#### **Standard Concentration**

2 mg/mL

#### **Administration Duration**

00:03 (hh:mm)

#### **Maximum Rate of Administration**

0.5 mg/kg/min **And**

#### **Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

##### *IV Direct- Doses greater than or equal to 1 mg*

#### **Standard Concentration**

10 mg/mL [Supplied in Standard Concentration]

#### **Administration Duration**

00:03 (hh:mm)

#### **Maximum Rate of Administration**

0.5 mg/kg/min

#### **Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Continuous Infusion- Patients less than or equal to 2 kg***Standard Concentration**

0.5 mg/mL

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Continuous Infusion- Patients greater than 2 kg***Standard Concentration**

2 mg/mL

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

*ganciclovir***HIGH ALERT, EXTRAVASATION RISK / IRRITANT**[Go to IWK Hazardous Drug Classification](#)*Administration Information**IV Intermittent Infusion***Standard Concentration**

5 mg/mL [Standard Concentration Prepared by Pharmacy]

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*gentamicin***EXTRAVASATION RISK / IRRITANT***Administration Information**IV Intermittent Infusion***Standard Concentration**

1 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:30 (hh:mm)

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*Intramuscular***Standard Concentration**

IM 40 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Comment**

- **Inject into large muscle**
- **IM injection is associated with variable absorption, especially in the very small neonate. Use IM route only in exceptional circumstances when IV route is not available**

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

*glucagon*

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

**NOTE: 1000 microgram = 1 mg = 1 unit**

*Administration Information**IV Direct***Standard Concentration**

0.2 mg/mL

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

*IV Continuous Infusion***Standard Concentration**

40 micrograms/mL

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

**Comment**

Do not mix with 0.9% NaCl

*Subcutaneous / Intramuscular***Standard Concentration**

Subcut/IM 1 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

**Comment**

Subcutaneous is preferred route of admin in severe hypoglycemia.

*Compatibility Information***Compatible Solutions**

5% Dextrose in Water (D5W)

---

*glycopyrrolate**Administration Information**IV Direct- Doses less than 20 micrograms***Standard Concentration**

50 micrograms/mL

**Administration Duration**

00:03 (hh:mm)

*IV Direct- Doses greater than or equal to 20 micrograms***Standard Concentration**

200 micrograms/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

*haemophilus B conjugate vaccine*

Vial contains 10 micrograms/0.5 mL (20 microgram/mL). Usual dose is 0.5 mL (10 micrograms)

*Administration Information**Intramuscular***Standard Concentration**

IM 20 micrograms/mL [Supplied in Standard Concentration]

*heparin***HIGH ALERT****For more information on preparing heparin bags when required concentration is not available, go to [Preparing Dextrose and Electrolyte Solutions \(with and without Heparin\) After-Hours](#)***Administration Information**IV Continuous Infusion- Systemic Anticoagulation***Standard Concentration**

50 units/mL(D5W) [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Continuous Infusion- If NaCl 0.9% diluent is required***Standard Concentration**

50 unit(s)/mL

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*Continuous Infusion (Fluid)- CVAD Patency Maintenance (PICCs 2 french and smaller)***Standard Concentration**

1 unit(s)/mL [Standard Concentration Prepared by Pharmacy]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**Accessible from pharmacy/pyxis [OR](#) via global find after hours. **Nursing do NOT have to prepare this.***hyaluronidase**Administration Information**Subcutaneous***Standard Concentration**

Subcutaneous 150 unit(s)/mL [Supplied in Standard Concentration]

**Comment**



- Prepare 5 syringes of 30 units (0.2 mL)
- Use a new needle for each injection.
- Wait 10-15 minutes and inject 3-5 mL 0.9% NaCl into each injection site

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl)

---

## hydrALAZINE

### HIGH ALERT

### Administration Information

#### IV Intermittent Infusion

#### Standard Concentration

1 mg/mL

#### Administration Duration

00:10 (hh:mm)

#### Maximum Rate of Administration

0.2 mg/kg/min

#### Monitoring

Level 3: Level 2 and continuous ECG

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl)

---

## hydrocortisone

### Administration Information

#### IV Direct- Doses less than 2.5 mg

#### Standard Concentration

1 mg/mL

#### Administration Duration

00:03 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### IV Direct- Doses 2.5 to 25 mg

#### Standard Concentration

5 mg/mL

#### Administration Duration

00:03 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### IV Direct- Doses greater than 25 mg

#### Standard Concentration

50 mg/mL [Supplied in Standard Concentration]

#### Administration Duration

00:03 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

## HYDRomorphone

### HIGH ALERT

**Reserved/Restricted : Controlled release capsules- prescribing and management is restricted to prescribers with Pediatric Acute Pain Service (APS), Pediatric Advanced Care Team (PACT), and hematology/oncology.**

### Administration Information

#### IV Direct- Doses less than 0.1 mg

##### Standard Concentration

0.05 mg/mL

##### Administration Duration

00:05 (hh:mm)

#### IV Direct- Doses greater than or equal to 0.1 mg

##### Standard Concentration

0.2 mg/mL

##### Administration Duration

00:05 (hh:mm)

#### IV Continuous Infusion- Patients less than or equal to 20 kg

##### Standard Concentration

0.05 mg/mL

##### Monitoring

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

##### Comment

When continuous infusion is running, bolus (intermittent) doses can be administered over 5 minutes using "BOLUS" function.

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

### Additional Information

#### Potential Hazards of Administration

- Rapid injection may result in severe respiratory depression and hypotension
  - Bradycardia, hypotension
  - CNS depression
  - Bronchospasm; respiratory depression
  - Nausea, vomiting, itchiness
  - Injection site reaction
- 

## ibuprofen

### Special Access

**The administration guidelines below are based on the use of ibuprofen lysine (NeoProfen)**

### Administration Information

#### IV Intermittent Infusion

##### Standard Concentration

5 mg/mL

##### Administration Duration

00:15 (hh:mm)

##### Comment

- Pharmacy does not prepare due to limited stability

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

### *indomethacin*

**Special Access, EXTRAVASATION RISK / IRRITANT**

**Reserved/Restricted : Injectable: Neonatology**

### Administration Information

#### *IV Intermittent Infusion*

#### Standard Concentration

0.05 mg/mL

#### Administration Duration

00:30 (hh:mm)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl)

---

### *insulin, human regular*

**HIGH ALERT**

**Do Not Filter**

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

### Administration Information

#### *IV Continuous Infusion- HyperGLYCEMIA with 0.9% NaCl as diluent*

#### Standard Concentration

0.08 unit(s)/mL

#### Monitoring

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

#### Comment

**USE HUMULIN R BRAND. PREPARATION IN A SYRINGE IS PREFERRED**

#### IMPORTANT INFORMATION REGARDING PRIMING:

- [New IV lines \(for Syringe only\)](#): Prime new IV line with insulin solution then prime once more with an additional 1 mL of insulin solution before connecting to the IV site.
- [Syringe change only \(no line change\)](#): Prepare solution, label, attach syringe to tubing on an existing line and administer.

#### *IV Continuous Infusion- HyperKALEMIA with D5W as diluent*

#### Standard Concentration

0.08 unit(s)/mL

#### Monitoring

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

#### Comment

**USE HUMULIN R BRAND. PREPARATION IN A SYRINGE IS PREFERRED**

#### IMPORTANT INFORMATION REGARDING PRIMING:

- New IV lines (for Syringe only): Prime new IV line with insulin solution then prime once more with an additional 1 mL of insulin solution before connecting to the IV site.
- Syringe change only (no line change): Prepare solution, label, attach syringe to tubing on an existing line and administer.

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

## ketamine

### HIGH ALERT

**Reserved/Restricted : Anaesthesiology, ED physicians, Intensivists in PICU, Pediatric Advanced Care Team (PACT)**

### Administration Information

#### IV Continuous Infusion

#### Standard Concentration

2 mg/mL

#### Monitoring

Level 3: Level 2 and continuous ECG

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

## levetiracetam

### Administration Information

#### IV Intermittent Infusion

#### Standard Concentration

15 mg/mL

#### Administration Duration

00:15 (hh:mm)

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

## levocarnitine

### Administration Information

#### IV Direct

#### Standard Concentration

200 mg/mL [Supplied in Standard Concentration]

#### Administration Duration

00:03 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl)

---

## LORazepam

### Administration Information

*IV Direct- Doses less than 0.25 mg*

**Standard Concentration**

0.1 mg/mL

**Administration Duration**

00:05 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

- Dextrose (D5W) is the **ONLY** solution to be used for dilution and flushing
- Do not mix or flush with 0.9% sodium chloride

*IV Direct- Doses greater than or equal to 0.25 mg***Standard Concentration**

1 mg/mL

**Administration Duration**

00:05 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

- Dextrose (D5W) is the **ONLY** solution to be used for dilution and flushing
- Do not mix or flush with 0.9% sodium chloride

*Compatibility Information***Compatible Solutions**

5% Dextrose in Water (D5W)

*magnesium sulfate***HIGH ALERT***Administration Information**IV Intermittent Infusion***Standard Concentration**

40 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

02:00 (hh:mm)

*IV Intermittent Infusion / Loading Dose (followed by continuous infusion)***Standard Concentration**

40 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:30 (hh:mm)

*IV Continuous Infusion***Standard Concentration**

40 mg/mL [Supplied in Standard Concentration]

*meropenem***Reserved/Restricted : Infectious Disease***Administration Information**IV Intermittent Infusion***Standard Concentration**

20 mg/mL

**Administration Duration**

00:30 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Compatibility Information****Compatible Solutions**

0.9% Sodium Chloride (NaCl)

---

**metroNIDAZOLE****Administration Information****IV Intermittent Infusion****Standard Concentration**

5 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

**midazolam****HIGH ALERT****Administration Information****IV Direct- Doses less than 0.1 mg****Standard Concentration**

0.05 mg/mL

**Administration Duration**

00:05 (hh:mm)

**IV Direct- Doses 0.1 to 0.5 mg****Standard Concentration**

0.2 mg/mL

**Administration Duration**

00:05 (hh:mm)

**IV Direct- Doses greater 0.5 mg****Standard Concentration**

1 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:05 (hh:mm)

**IV Continuous Infusion- Patients less than or equal to 2 kg****Standard Concentration**

0.2 mg/mL

**IV Continuous Infusion- Patients greater than 2 kg****Standard Concentration**

1 mg/mL [Supplied in Standard Concentration]

**Intramuscular****Standard Concentration**

1 mg/mL [Supplied in Standard Concentration]

**Compatibility Information****Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

**Additional Information**

**Potential Hazards of Administration**

- Rapid IV administration or concurrent narcotic administration may cause severe hypotension and/or seizures in neonates
- Cardiac arrest, hypotension, bradycardia
- Respiratory depression, apnea, oxygen desaturation
- Myoclonus occurs in ~8% premature infants
- Paradoxical reaction may occur, including hyperactive or aggressive behavior
- Pain and local reaction at injection site- avoid extravasation

**Monitoring Conditions**

- Respiratory rate, oxygen saturation
- Heart rate, blood pressure

---

*milrinone***HIGH ALERT***Administration Information**IV Intermittent Infusion (Loading Dose)- Patients less than or equal to 2 kg***Standard Concentration**

0.2 mg/mL

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 3: Level 2 and continuous ECG

*IV Intermittent Infusion (Loading Dose)- Patients greater than 2 kg***Standard Concentration**

0.4 mg/mL

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 3: Level 2 and continuous ECG

*IV Continuous Infusion- Patients less than or equal to 2 kg***Standard Concentration**

0.2 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

**Central Line PREFERRED***IV Continuous Infusion- Patients greater than 2 kg***Standard Concentration**

0.4 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

**Central Line PREFERRED***Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

*Additional Information***Potential Hazards of Administration**

- Hypotension
- Increased heart rate
- Arrhythmias
- Bronchospasm

---

## *morphine*

**HIGH ALERT**

**Reserved/Restricted : Extended release capsules- prescribing and management is restricted to prescribers with Pediatric Acute Pain Service (APS), Pediatric Advanced Care Team (PACT), and hematology/oncology.**

### *Administration Information*

#### *IV Direct- Doses less than 1 mg*

**Standard Concentration**

0.4 mg/mL

**Administration Duration**

00:05 (hh:mm)

#### *IV Direct- Doses greater than 1 mg*

**Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:05 (hh:mm)

#### *IV Continuous Infusion- Patients less than or equal to 2 kg with D5W as diluent*

**Standard Concentration**

0.15 mg/mL

**Monitoring**

As per clinical order set IWK MOCO

**Comment**

When continuous infusion is running, bolus (intermittent) doses can be administered over 5 minutes using "BOLUS" function. Bolus may be administered over seconds in critical care areas.

#### *IV Continuous Infusion- Patients greater than 2 kg with D5W as diluent*

**Standard Concentration**

1 mg/mL

**Monitoring**

As per clinical order set IWK MOCO

**Comment**

When continuous infusion is running, bolus (intermittent) doses can be administered over 5 minutes using "BOLUS" function. Bolus may be administered over seconds in critical care areas.

### *Subcutaneous*

**Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

### *Compatibility Information*

**Compatible Solutions**

0.45% Sodium Chloride (NaCl), 0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

---

## *naloxone*

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

### *Administration Information*

#### *IV Direct*

**Standard Concentration**

0.4 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

30 seconds

**Monitoring**



Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

Preferred route of administration

*Intramuscular***Standard Concentration**

0.4 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

*neostigmine**Administration Information**IV Direct***Standard Concentration**

0.5 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*Subcutaneous / Intramuscular***Standard Concentration**

0.5 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

*nitroprusside***HIGH ALERT***Administration Information**IV Continuous Infusion- Patients less than or equal to 2 kg***Standard Concentration**

0.15 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

**Comment**

- Protect from light, cover infusion with the light protective sleeve provided with the drug. It is not necessary to wrap tubing.

*IV Continuous Infusion- Patients greater than 2 kg***Standard Concentration**

1 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

**Comment**

- Protect from light, cover infusion with the light protective sleeve provided with the drug. It is not necessary to wrap tubing.

*Compatibility Information***Compatible Solutions**

5% Dextrose in Water (D5W)

---

## norepinephrine

### HIGH ALERT, EXTRAVASATION RISK / IRRITANT

#### Administration Information

*IV Continuous Infusion- For patients 2 kg or less OR as prescribed for Cardiac Surgery Patients*

##### Standard Concentration

0.008 mg/mL

##### Monitoring

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

##### Central Line PREFERRED

##### Comment

Administration through umbilical arterial catheter is not recommended

*IV Continuous Infusion- For patients greater than 2 kg and up to 20 kg*

##### Standard Concentration

0.04 mg/mL

##### Monitoring

Level 3: Level 2 and continuous ECG

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

##### Central Line PREFERRED

##### Comment

Administration through umbilical arterial catheter is not recommended

#### Compatibility Information

##### Compatible Solutions

5% Dextrose in Water (D5W)

---

## octreotide

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

#### Administration Information

*IV Continuous Infusion*

##### Standard Concentration

5 micrograms/mL

##### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

*IV Intermittent Infusion*

##### Standard Concentration

5 micrograms/mL

##### Administration Duration

00:15 (hh:mm)

##### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### Compatibility Information

##### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

## palivizumab

## Administration Information

### Intramuscular

#### Standard Concentration

IM 100 mg/mL [Supplied in Standard Concentration]

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

## pantoprazole

### Administration Information

#### IV Direct

#### Standard Concentration

4 mg/mL [Supplied in Standard Concentration]

#### Administration Duration

00:03 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

### Compatibility Information

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

---

## penicillin G

### EXTRAVASATION RISK / IRRITANT

- 0.1 million units= 0.1 MU (note : displayed in infusion pumps as MU)= 100,000 units/mL

### Administration Information

#### IV Intermittent Infusion- Using 1 million unit Vial

#### Standard Concentration

0.1 millionunits/mL [Supplied in Standard Concentration]

#### Administration Duration

00:30 (hh:mm)

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Intramuscular- Doses less than 0.05 million units

#### Standard Concentration

0.1 millionunits/mL [Supplied in Standard Concentration]

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### Comment

- Inject into a large muscle

#### Intramuscular- Doses greater than or equal to 0.05 million units

#### Standard Concentration

0.5 millionunits/mL [Supplied in Standard Concentration]

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Comment**

- Inject into a large muscle

**Compatibility Information****Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

**PHENobarbital****EXTRAVASATION RISK / IRRITANT****Administration Information****IV Intermittent Infusion- Loading Dose****Standard Concentration**

30 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:20 (hh:mm)

**Maximum Rate of Administration**

1 mg/kg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**IV Intermittent Infusion- Doses less than 15 mg- MAINTENANCE****Standard Concentration**

5 mg/mL

**Administration Duration**

00:15 (hh:mm)

**Maximum Rate of Administration**

1 mg/kg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**IV Intermittent Infusion- Doses greater than or equal to 15 mg- MAINTENANCE****Standard Concentration**

30 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:15 (hh:mm)

**Maximum Rate of Administration**

1 mg/kg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

**Compatibility Information****Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

---

## phentolamine

### Administration Information

#### Subcutaneous

**Standard Concentration**

Subcutaneous 0.5 mg/mL

**Comment**

- Remove 0.2 mL from 5 mg/mL vial.
- Add 1.8 mL of 0.9% sodium chloride to provide final concentration of 0.5 mg/mL.
- Prepare 5 x 0.2 mL syringes and discard any remaining solution.

### Compatibility Information

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

## phenytoIN

**EXTRAVASATION RISK / IRRITANT****FILTER** 0.22 micron in-line filter

- Avoid administration via peripherally inserted central catheter (PICC) line if possible because risk of precipitation –consult with the PICC/central line nurse if need to administer via PICC line
- Go to [Institute for Safe Medication Practices Canada Safety Bulletin: IV Phenytoin: Rate of Administration is Critical](#)

### Administration Information

#### IV Intermittent Infusion- Loading Dose

**Standard Concentration**

10 mg/mL

**Administration Duration**

00:40 (hh:mm)

**Maximum Rate of Administration**

0.5 mg/kg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### IV Intermittent Infusion- Doses less than 5 mg- MAINTENANCE DOSE

**Standard Concentration**

2.5 mg/mL

**Administration Duration**

00:15 (hh:mm)

**Maximum Rate of Administration**

0.5 mg/kg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### IV Intermittent Infusion- Doses greater than or equal to 5 mg- MAINTENANCE DOSE

**Standard Concentration**

10 mg/mL

**Administration Duration**

00:15 (hh:mm)

**Maximum Rate of Administration**

0.5 mg/kg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl)

*Additional Information***Comments**

- Prepare dilution just prior to administration. Infusion must be completed within 4 hours of mixing.

*phytonadione**Administration Information**Subcutaneous / Intramuscular***Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

**Intramuscular is the preferred route of administration**

*IV Intermittent Infusion***Standard Concentration**

2 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:15 (hh:mm)

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

*piperacillin|tazobactam***EXTRAVASATION RISK / IRRITANT**

**All concentrations (mg/mL) are based on the piperacillin component**

**4.5 grams = 4 grams of piperacillin and 0.5 g of tazobactam 4.5 gram vial is stocked in pediatric care areas**

*Administration Information**IV Intermittent Infusion***Standard Concentration**

80 mg/mL

**Administration Duration**

00:30 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

## potassium chloride

### HIGH ALERT

1 mmol potassium = 1 mEq potassium

Note: 10 mmol/litre = 10 mEq/litre = 1 mEq/100 mL = 1 mEq%

[CLICK HERE For additional important information on potassium chloride containing solutions AND please refer to September 2019 parenteral monograph \(to be reviewed in Spring 2020\).](#)

**Potassium concentration, administration time, infusion rate and route are dependent upon clinical indication and patient's clinical status**

- All sources of infusing potassium should be used to calculate mmol/kg/hr the patient is receiving including, but not limited to, oral supplementation, TPN, IV maintenance solutions, and potassium infusions.

[Available potassium chloride containing IV solutions at IWK Supply and Distribution](#)

[Information on preparing potassium chloride IV solution after hours](#)

### Administration Information

#### IV Intermittent Infusion- NICU and PICU ONLY

##### Standard Concentration

1 mmol/mL [Standard Concentration Prepared by Pharmacy]

##### Administration Duration

01:00 (hh:mm)

##### Central Line Only

#### IV Continuous Infusion- NICU and PICU ONLY

##### Standard Concentration

1 mmol/mL [Standard Concentration Prepared by Pharmacy]

##### Central Line Only

#### Potassium Containing Maintenance Solutions

##### Comment

The following maximum concentrations apply:

**Peripheral:** 60 mmol/L or 0.06 mmol/mL

**Central:** 120 mmol/L or 0.12 mmol/mL

## procainamide

### HIGH ALERT

### Administration Information

#### IV Intermittent Infusion

##### Standard Concentration

4 mg/mL

##### Administration Duration

01:00 (hh:mm)

##### Monitoring

Level 3: Level 2 and continuous ECG

#### IV Continuous Infusion

##### Standard Concentration

4 mg/mL

##### Maximum Rate of Administration

30 mg/min

##### Monitoring

Level 3: Level 2 and continuous ECG

### Compatibility Information

**Compatible Solutions**

0.9% Sodium Chloride (NaCl)

---

### propranolol

**HIGH ALERT**

#### Administration Information

##### IV Intermittent Infusion- Doses less than 0.5 mg

**Standard Concentration**

0.05 mg/mL

**Administration Duration**

00:10 (hh:mm)

**Monitoring**

Level 3: Level 2 and continuous ECG

##### IV Intermittent Infusion- Doses greater than or equal to 0.5 mg

**Standard Concentration**

1 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:10 (hh:mm)

**Monitoring**

Level 3: Level 2 and continuous ECG

### Compatibility Information

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

---

### protamine

#### Administration Information

##### IV Intermittent Infusion

**Standard Concentration**

10 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:10 (hh:mm)

**Maximum Rate of Administration**

5 mg/min

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

---

### pyridoxine

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

#### Administration Information

##### IV Direct

**Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

00:03 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)



### *Intramuscular*

**Standard Concentration**

100 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

**Comment**

- Inject into a large muscle
- 

### *rifampin*

**Special Access**

#### *Administration Information*

#### *IV Intermittent Infusion*

**Standard Concentration**

6 mg/mL

**Administration Duration**

01:00 (hh:mm)

#### *Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

### *rocuronium*

**HIGH ALERT**

#### *Administration Information*

#### *IV Direct- Doses less than 1 mg*

**Standard Concentration**

1 mg/mL

**Administration Duration**

5 seconds

**Monitoring**

Level 3: Level 2 and continuous ECG

#### *IV Direct- Doses greater than or equal to 1 mg*

**Standard Concentration**

10 mg/mL [Supplied in Standard Concentration]

**Administration Duration**

5 seconds

**Monitoring**

Level 3: Level 2 and continuous ECG

#### *IV Continuous Infusion- Patients less than or equal to 2 kg*

**Standard Concentration**

2 mg/mL

**Monitoring**

Level 3: Level 2 and continuous ECG

#### *IV Continuous Infusion- Patients greater than 2 kg*

**Standard Concentration**

10 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 3: Level 2 and continuous ECG

#### *Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

---

*salbutamol**Administration Information**IV Intermittent Infusion***Standard Concentration**

0.02 mg/mL

**Administration Duration**

00:20 (hh:mm)

**Monitoring**

Level 3: Level 2 and continuous ECG

*Compatibility Information***Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

---

*sildenafil***HIGH ALERT**

**Reserved/Restricted : Intensivists, Neonatologists and Cardiology for initiation**

*Administration Information**IV Continuous Infusion***Standard Concentration**

0.4 mg/mL

**Maximum Rate of Administration**

0.4 mg/kg/hour

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

**Comment**

Note: Recommended to administer loading dose over 3 hours

*Compatibility Information***Compatible Solutions**

5% Dextrose in Water (D5W)

---

*sodium bicarbonate*

[Go to IWK Regional Poison Centre Provincial Antidote Kit for information on antidote administration](#)

*Administration Information**IV Intermittent Infusion***Standard Concentration**

0.5 mmol/mL [Supplied in Standard Concentration]

**Maximum Rate of Administration**

0 mmol/kg/hour

*IV Continuous Infusion***Standard Concentration**

0.5 mmol/mL [Supplied in Standard Concentration]

**Maximum Rate of Administration**

0 mmol/kg/hour

### *Compatibility Information*

#### **Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

---

### *succinylcholine*

#### **HIGH ALERT**

#### *Administration Information*

##### *IV Direct*

#### **Standard Concentration**

1 mg/mL [Standard Concentration Prepared by Pharmacy]

#### **Administration Duration**

10 seconds

#### **Monitoring**

Level 3: Level 2 and continuous ECG

#### *Additional Information*

#### **Potential Hazards of Administration**

- Transient cardiac arrhythmias, especially bradycardia in children (increased incidence with repeat doses)
-

## *tobramycin*

### *Administration Information*

#### *IV Intermittent Infusion*

**Standard Concentration**

2 mg/mL

**Administration Duration**

00:30 (hh:mm)

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

#### *Intramuscular*

**Standard Concentration**

IM 40 mg/mL [Supplied in Standard Concentration]

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

**Comment**

- Inject into large muscle
- IM injection is associated with variable absorption, especially in the very small neonate. Use IM route only in exceptional circumstances when IV route is not available

### *Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

---

## *vancomycin*

**EXTRAVASATION RISK / IRRITANT**

### *Administration Information*

#### *IV Intermittent Infusion- Doses less than or equal to 500 mg*

**Standard Concentration**

5 mg/mL

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

### *Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 10% Dextrose in Water (D10W), 5% Dextrose in Water (D5W)

---

## *vasopressin*

**HIGH ALERT, EXTRAVASATION RISK / IRRITANT**

**1 unit = 1000 milliunits**

**Note: different concentrations depending on the indications and weight**

### *Administration Information*

#### *IV Continuous Infusion- Patients less than or equal to 3 kg*

**Standard Concentration**

0.16 unit(s)/mL

#### Monitoring

Level 4: Level 3 and invasive hemodynamic monitoring and/or respiratory support (continuous)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### *IV Continuous Infusion- Patients greater than 3 kg*

#### Standard Concentration

1 unit(s)/mL

#### Monitoring

Level 4: Level 3 and invasive hemodynamic monitoring and/or respiratory support (continuous)

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### *Subcutaneous / Intramuscular*

#### Standard Concentration

20 unit(s)/mL [Supplied in Standard Concentration]

#### Monitoring

Level 2 – Level 1 but with additional monitoring parameters (e.g. pain or sedation scores blood glucose urine output etc.) and/or increased frequency of vital signs

The infusion site **must** be inspected every 30-60 minutes and documented when in use and if extravasation or infiltration is suspected. If extravasation occurs, refer to [Management of Extravasation](#) policy.

#### *Compatibility Information*

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W)

## *voriconazole*

### *Administration Information*

#### *IV Intermittent Infusion*

#### Standard Concentration

2 mg/mL

#### Maximum Rate of Administration

3 mg/kg/hour

#### Monitoring

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

#### Comment

**ADMINISTRATION DURATION IS DOSE DEPENDENT BASED ON MAXIMUM RATE OF 3 mg/kg/hr (see calculation below)**

#### To calculate the duration of the infusion:

1. Calculate maximum mg/hour based on patient's weight:  
 $3 \text{ mg/kg/hr} \times \text{___kg} = \text{___ mg/hr}$
2. Calculate administration time in hours based on dose ordered:  
 $\text{___ mg (dose ordered)} \div \text{___ mg/hr (response from step \#1)} = \text{___ hours (administration time)}$

#### *Compatibility Information*

#### Compatible Solutions

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

#### *Additional Information*

#### Potential Hazards of Administration

- Anaphylactoid type infusion reactions – flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faint, nausea, pruritis, rash, hypotension

## *zidovudine*

### *Administration Information*

#### *IV Intermittent Infusion*

**Standard Concentration**

1 mg/mL

**Administration Duration**

01:00 (hh:mm)

**Monitoring**

Level 1: Temperature, Heart Rate, Respiration Rate, Blood Pressure, Oxygen Saturation (every 4 hours)

### *Compatibility Information*

**Compatible Solutions**

0.9% Sodium Chloride (NaCl), 5% Dextrose in Water (D5W), Lactated Ringer's (LR)

---

© 2022 IWK Health. All rights reserved.